Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
Study sponsor: Eledon Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-07-31Actual
Enrollment · participants24Actual
Source updated2024-03-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.